





Robert Greene Sterne Jorge A. Goldstein Jorge A. Goldstein Joavid K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. G. Durkin Michael B. A. Gimbala Michael B. A. Goldstein John M. Covert Robert C. Millonig Donald J. Featherist G. Steffe Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowin Peter A. Jackwin Peter A

Vincent L. Capuano Flizabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Theodore A. Wood Edward W. Yee Grant E. Reed Jason D. Eisenberg Fract L. Muller On E. Wright LuAnne M. De Santis Helene C. Carlson Cynthia M. Bouchez Jimothy A. Doyle Gaby L. Longsworth Lori A. Gordón Laura A. Vogel Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose

December 29, 2008

James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler Jenks
Paul A. Calvo
C: Matthew Rozier
Randall K. Baldwin
Lori M. Brandes
Jeffrey K. Mills
Jeremy M. Klass
Stephanie L. Elmer
Mita Mukherjee*
Scott M. Woodhouse*
Jeremiah B. Frueauf
Christian A. Camarce
Richard D. Coller III

Anne M. Georgalas
'atrick P. Hansen
'ooss G. Hicks
'deisha Hylton-Rodic
Jonnie Nannenga-Combs
'dyssa K. Sandrowitz*
onathan M. Strang*
shan P. Weerakoon*
salvador M. Bezos*
usstin T. Sher
Byron L. Pickard
ikhard B. Almon*
*
struce B. Vance

Registered Patent Agents « Karen R. Markowicz Peter A. Socarras Danielle L. Letting Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana Robert E. Bakin /asser Mourtada Lellie K. DiNapoli ulie L. Blum Lynthia L. DeRenzo Uyson C. Fuller Dmar F. Amin hovon I. Ashraf

Of Counsel
Cou

*Admitted only in Maryland * Admitted only in Virginia *Practice Limited to

WRITER'S DIRECT NUMBER: (202) 772-8856 INTERNET ADDRESS: KMCCABE@SKGF.COM

Art Unit 1644

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Appl. No. 10/765,097; Filed: January 28, 2004

For: Means for Detection and Purification of CD8+T Lymphocyte

Populations Specific to Peptides Presented in the Context of HLA

Inventors:

LANG et al.

Our Ref:

2512.0240002/KWM/ROM (2102-183-DIV) -

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- 2. Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a);
- 3. 1 page of a paper copy of the substitute Sequence Listing;
- 4. A computer readable copy of the substitute Sequence Listing; and
- 5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

1

Sterne, Kessler, Goldstein & Fox PLL.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents December 29, 2008 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kevin W. McCabe Attorney for Applicants Registration No. 41,182

KWM/ROM:dbj Enclosures

920657_1.DOC



DUPLICATE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/765,097 01/28/2004		Francois Lang	BECK1170-1	9827	
Beckman Coulter, Inc. c/o DLA PIPER US LLP Suite 1100 4365 Executive Drive San Diego, CA 92121-2133		EXAM	EXAMINER		
			DIBRINO, MAI	DIBRINO, MARIANNE NMN	
			ART UNIT	PAPER NUMBER	
		1644	1644		
		,			
•			MAIL DATE	DELIVERY MODE	
			12/04/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 2000
WWW.USDIO.000

APPLICATION NO. /CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.	
10765097	1/28/04	LANG ET AL.	BECK1170-1	

EXAMINERDiBrino Marianne

. ART UNIT	PAPER	
1644	20081201	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- 1. Electronically submitted through EFS-Web (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. Mailed to:

Mail Stop Sequence Commissioner for Patents P.O. Box 22313 1450 Alexandria, VA 22313 1450

3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:

U.S. Patent and Trademark Office

Mail Stop Sequence

Customer Window

Randolph Building

401 Dulaney Street

Alexandria, VA 22314

Any inquiry concerning this communication should be directed to Marianne DiBrino at telephone number 571-272-0842. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, O'Hara B. Eileen, can be reached on 571-272-0848.

/Michael Szperka/ Primary Examiner, Art Unit 1644



Application No.	Applicant(s)		
19/765,097	Lang et al.		
Examiner	Art Unit		
Marianne DiBrino	1644		

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
×	7. Other: Applicant must provide data at fields <150> and <151> for all parent priority document

Applicant Must Provide:

- Arrimitiation substitute computer readable form (CRF) copy of the "Sequence Listing".
- Arrinitial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951


For CRF Submission Help, call (571) 272-2510

Patentin Software Program Support

Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845

PatentIn Software is Available At www.USPTO.gov

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY





Application/Control No.	Applicant(s)
10/765,097	Lang et al.
Examiner	Art Unit
Marianna DiBrina	1644

Sequence Count Sheet		Examiner	Art Unit	
		Marianne DiBrino	1644	
DATE OF COUNT Mark only one space below				
	(CRFN) (CRF is unreadable; use CRF Diskette Problem Report)			
	(CRFD) (CRF does not comply; use Notice to Comply)			
	(CRFR) (CRF required but none submitted; use Notice to Comply)			
	(bona fide) (second or subsequent letter to applicant reporting bona fide attempt to comply; use Notice to Comply and send copy of RSL)			
	(non bona fide) (second or subsequent letter to applicant reporting non-bona fide attempt to comply; use Notice to Comply and send copy of RSL)			
		·		
			-	
	· .	•		